crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 530978

Časopis

Autori: Awad, Tahany; Thorlund, Kristian; Hauser, Goran; Štimac, Davor; Mabrouk, Mahasen; Gluud, Christian
Naslov: "Real-Life" Comparison of Pegylated-Interferon 2a Versus 2b Combination Therapy of Chronic Hepatitis C Virus Reply
( "Real-Life" Comparison of Pegylated-Interferon 2a Versus 2b Combination Therapy of Chronic Hepatitis C Virus Reply )
Izvornik: Hepatology (Baltimore, Md.) (0270-9139) 53 (2011), 4; 1407-1407
Vrsta rada: pismo
Ključne riječi: Pegylated interferon alpha; Chronic hepatitis C; RCT
( Pegylated interferon alpha; Chronic hepatitis C; RCT )
Sažetak:
A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b) is most effective. We performed a systematic review of head-to-head randomized trials to assess the benefits and harms of the two treatments. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and LILACS through July 2009. Using standardized forms, two reviewers independently extracted data from each eligible trial report. We statistically combined data using a random effects meta-analysis according to the intention-to-treat principle. We identified 12 randomized clinical trials, including 5, 008 patients, that compared peginterferon alpha-2a plus ribavirin versus peginterferon alfa-26 plus ribavirin. Overall, peginterferon alpha-2a significantly increased the number of patients who achieved a sustained virological response (SVR) versus peginterferon alfa-26 (47% versus 41% ; risk ratio 1.11, 95% confidence interval 1.04-1.19 ; P = 0.004 [eight trials]). Subgroup analyses of risk of bias, viral genotype, and treatment history yielded similar results. The meta-analysis of adverse events leading to treatment discontinuation included 11 trials and revealed no significant differences between the two peginterferons. Conclusion: Current evidence suggests that peginterferon alpha-2a is associated with higher SVR than peginterferon alfa-2b. However, the paucity of evidence on adverse events curbs the decision to definitively recommend one peginterferon over the other, because any potential benefit must outweigh the risk of harm. (HEPATOLOGY 2010 ; 51:1176-1184.)
Izvorni jezik: eng
Rad je indeksiran u
bazama podataka:
Current Contents Connect (CCC)
MEDLINE
Scopus
SCI-EXP, SSCI i/ili A&HCI
Science Citation Index Expanded (SCI-EXP) (sastavni dio Web of Science Core Collectiona)
Kategorija: Znanstveni
Znanstvena područja:
Kliničke medicinske znanosti
URL Internet adrese: http://onlinelibrary.wiley.com/doi/10.1002/hep.24236/abstract
Broj citata:
Altmetric:
DOI: 10.1002/hep.24236
URL cjelovitog teksta:
Google Scholar:
Upisao u CROSBI: vlicul@medri.hr (vlicul@medri.hr), 19. Lis. 2011. u 13:49 sati



  Verzija za printanje   za tiskati


upomoc
foot_4